WATERTOWN, Mass. – C4 Therapeutics (C4T) today announced the appointment of Ryan B. Corcoran, M.D., Ph.D., to the Company’s Scientific Advisory Board (SAB).
“C4 Therapeutics has established a scientific advisory board of leading researchers and physicians and are excited to expand that expertise with the addition of Ryan Corcoran, a world leader in oncogenic signaling pathways,” said Andy Phillips, Ph.D., President and Chief Executive Officer of C4 Therapeutics. “As we look ahead to bringing our pipeline of targeted protein degraders into clinical trials, Ryan’s input will be instrumental to our success.”
“Protein degradation offers an opportunity to improve on the treatment options currently available to cancer patients and to offer treatment options to patients who have high unmet need and that lack options. I look forward to working closely with C4 Therapeutics as they translate their leading science into the clinical space,” said Ryan Corcoran, M.D., Ph.D.
Dr. Ryan Corcoran is the Director of the Gastrointestinal Cancer Center Program and the Scientific Director of the Termeer Center for Targeted Therapy at the Massachusetts General Hospital Cancer Center. He is an Associate Professor of Medicine at Harvard Medical School. Dr. Corcoran directs a research laboratory focused on the development of therapeutic strategies that target the specific mutations driving individual patients’ tumors and understanding molecular determinants of response or resistance to anti-cancer therapies. Dr. Corcoran’s laboratory is also studying new ways to utilize liquid biopsy, and specifically analysis of circulating tumor DNA, in the clinic to optimize how we deliver cancer care to individual patients. Dr. Corcoran received his M.D./Ph.D. from Stanford University and completed his residency in Internal Medicine at the Massachusetts General Hospital and his fellowship in Medical Oncology at the Dana Faber Cancer Institute and the Massachusetts General Hospital Cancer Center.
About C4 Therapeutics
C4 Therapeutics (C4T) is pioneering a new class of small-molecule drugs that selectively target disease-relevant proteins for degradation using the innate machinery of the cell. This targeted protein degradation approach has the potential to treat a range of diseases and offers advantages over traditional drugs, such as potential to minimize drug resistance, de-risked starting points, high potency and specificity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.
Caroline Rufo, Ph.D.